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Background: Tumor hypoxia is linked to invasion and metastasis but whether this associates with tumor growth
rate is not well understood. We aimed to study the relationship between hypoxia evaluated with the positron
emission tomography (PET) tracer [18F]EF5 and tumor growth. Our second goal was to assess the variability in the
uptake of [18F]EF5 in tumor between two scans.
Methods: Four human head and neck squamous cell carcinoma (UT-SCC) cell lines were xenografted in flank or
neck of nude mice, and tumor size was closely monitored over the study period. The tumors were clearly visible
when the first [18F]EF5 scan was acquired. After an exponential growth phase, the tumors were imaged again with
[18F]EF5 and also with 18F-fluorodeoxyglucose ([18F]FDG).
Results: There was a clear correlation between the percentage of tumor growth rate per day and the [18F]EF5
uptake in the latter scan (r = 0.766, p = 0.01). The uptake of [18F]EF5 in the first scan and the uptake of [18F]FDG did
not significantly correlate with the tumor growth rate. We also observed considerable variations in the uptake of
[18F]EF5 between the two scans.
Conclusions: The uptake of [18F]EF5 in the late phase of exponential tumor growth is associated with the tumor
growth rate in mice bearing HNC xenografts.
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Imaging of hypoxia with positron emission tomography
(PET) has been the subject of intense research in oncology
since hypoxic tumors tend to be more aggressive and have
a poorer prognosis than their non-hypoxic counterparts
[1]. In particular, poor oxygenation confers radioresistance
in head and neck cancer (HNC) [2]. Consequently, there
is a great need to develop an appropriate non-invasive
method to detect tumor hypoxia before the onset of radio-
therapy (RT) of HNC to help in the selection of patients
who are candidates for dose escalation protocols of hyp-
oxic tumors [3].* Correspondence: anmisi@utu.fi
1Turku PET Centre, Medicity Research Laboratory, University of Turku, Tykistökatu
6A, FI-20520 Turku, Finland
2Department of Otorhinolaryngology - Head and Neck Surgery, Turku
University Hospital, P.O. BOX 52, FI-20521 Turku, Finland
Full list of author information is available at the end of the article
© 2014 Silvoniemi et al.; licensee Springer. This
Attribution License (http://creativecommons.or
in any medium, provided the original work is pIntegrated positron emission tomography and com-
puted tomography (PET/CT) imaging with 18F-fluoro-
deoxyglucose ([18F]FDG) is increasingly used in patients
with HNC for pretreatment staging and monitoring of
therapy response [4]. PET imaging has been postulated
to be an ideal method also to detect tumor hypoxia,
but one major challenge has been to develop an opti-
mal PET tracer for this purpose [5]. Several PET tracers
have been tested recently for the detection of hypoxia,
for example 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-
pentafluoropropyl)-acetamide (EF5) labeled with 18F-
fluorine isotope. [18F]EF5 has been evaluated both in
preclinical and in clinical studies, and the initial results
have been encouraging [6-9].
Hypoxic tumors are thought to grow more rapidly
than non-hypoxic tumors, because hypoxia induces sev-
eral biological processes that promote tumor growth,is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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is a general feature of aggressive tumors together with
increased metabolism. This can be depicted with PET
imaging, although inflammatory reactions may contribute
to the signal. In line with this theory, a high uptake of
[18F]FDG in neoplastic tissue has correlated with tumor
growth rate both in experimental and in several solid tu-
mors [11,12] and is thought to be associated with poor
outcome.
While tumor size is another negative prognostic factor
in HNC, several studies have attempted to investigate
the relationship between tumor size and oxygenation
with invasive and non-invasive methods. In a series of
classical polarographic studies utilizing pO2 histography,
it was found that the degree of hypoxia was not related to
tumor size [13]. Similarly, the uptake of hypoxia tracer
18F-fluoromisonidazole ([18F]FMISO) has not been associ-
ated with tumor size in several experimental and clinical
studies [14-16]. In view of these findings and the heteroge-
neous distribution of hypoxia and proliferation within tu-
mors, it has been deemed necessary to study the extent of
the PET tracer based metabolic and hypoxic subvolumes
over time. This is due to the current practice of inten-
sity modulated and dose painting techniques which
permit the adaptation of volume changes to the initial
plan during RT.
Bearing these factors in mind, we aimed to determine
the uptake of [18F]EF5 and [18F]FDG in relation to
growth rate in an experimental HNC tumor model. Sec-
ondly, we were interested in examining the variability of
uptake of the hypoxia tracer over time in an attempt to
assess its feasibility for adaptive RT plans where changes




Four squamous cell carcinoma cell lines (UT-SCC)
established in the University of Turku were used in this
study. Different cell lines were utilized to mimic the gen-
etic variability of malignant head and neck tumors in a
clinical setting. The characteristics of the cell lines are
presented in Table 1. Cells were routinely cultured in
Dulbecco’s modified Eagle’s medium (Gibco) containing
L-glutamine (Gibco), non-essential amino acids (Gibco),
streptomycin, penicillin (Gibco), and 10% FBS (Gibco)Table 1 Characteristics of the cell lines
Cell line Gender Primary tumor location
UT-SCC 8 Male Supraglottic larynx
UT-SCC 34 Male Supraglottic larynx
UT-SCC 70 Male Hypopharynx
UT-SCC 74A Male Mobile tongueat +37°C in a humidified air atmosphere containing
5% CO2. For detaching and plating, cells were washed
with PSB, trypsinized (Trypsin-EDTA in HBSS, Gibco),
and centrifuged at 1,300 rpm for 5 min [7].
The animal procedures were performed as previously
described [7]. Male nude mice (Athymic nu/nu, Harlan,
The Netherlands), weighing 28.9 ± 4.0 g (mean ± SD),
were total-body irradiated with 4 Gy 1 day before the
tumor induction in order to suppress the immune system
and facilitate tumor growth. Tumor cells (1−10 × 106)
were subcutaneously injected into the flank or neck of
each mouse. Mice were maintained in IVC animal cages
under controlled pathogen-free environmental conditions
(21°C, humidity 55 ± 5%, and lights on from 6:00 a.m. to
6:00 p.m.) with free access to water and standard food.
The animals were observed on a daily basis and tumor
sizes were closely monitored over the study period (V =
(π/6) × a × c × b). The starting and end points of expo-
nential growth periods were determined from the tumor
growth curves. The percentage of tumor growth rate per
day from the exponential growth period was calculated.
The experiment procedures were reviewed by the local
Ethics Committee on Animal Experimentation of the
University of Turku and approved by the Provincial State
Office of Western Finland.
Synthesis of PET tracers
[18F]EF5 was synthesized as previously described [8].
The specific activity of [18F]EF5, decay corrected to the
end of synthesis, exceeded 3.7 GBq/μmol. Radiochemical
purity was higher than 98.5% in every production batch.
[18F]FDG was synthesized from mannosyl triflate using
a nucleophilic method. Radiochemical purity exceeded
95% in every production batch.
PET/CT imaging
The tumors were clearly visible when they were first im-
aged with [18F]EF5. Mice were anesthetized with 2.5%
isoflurane, and body temperature was maintained using
a heating pad. PET/CT scans were performed with the
Inveon multimodality PET/CT scanner (Siemens Medical
Solutions, Knoxville, TN, USA). Following a transmission
scan for attenuation correction using the CT modality, an
emission scan was acquired in the 3D list mode with an
energy window of 350 to 650 keV. Dynamic 80 min long
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300 s, and 4 × 600 s and reconstructed with an OSEM
two-dimensional iterative algorithm. A second [18F]EF5
scan and an [18F]FDG scan were performed on consecu-
tive days after the clear exponential growth period of tu-
mors. Mice were injected with [18F]EF5 (11.1 ± 1.9 MBq)
or [18F]FDG (10.9 ± 2.8 MBq) (mean ± SD). The mice
were sacrificed after the last PET/CT scan and tissue oxy-
gen measurements (see below).
Data analysis
The Inveon Research Workplace Image Analysis software
(Siemens Medical Solutions, Knoxville, TN, USA) was
used to analyze the PET/CT images. The images were
summed from 60 to 80 min post injection, and the tumors
were delineated in the images using the CT image as an
anatomical reference. Volumes of interest (VOIs) were
drawn over whole tumors and then transformed to the
PET image. Radioactivity uptake was calculated as the per-
centage injected dose per gram tissue (%ID/g) in the
whole tumor. In addition, the hottest cluster containing
voxels with the highest uptake in 10% of the tumor vol-
ume (HC 10%) was determined using the same uptake
unit (%ID/g).
Direct tissue oxygen measurements
Licox® (GMS, Kiel-Mielkendorf, Germany) system was
used for direct tissue oxygenation measurements with
the Licox CC1.P1 probe with temperature sensor being
used in this study. It was 0.65 mm in diameter and had
an 18-mm2 oxygen sensitive area, which produced an es-
timate of nearby tissue oxygen tension (Integra Neuro-
science). Two of the tumors were measured. Mice were
anesthetized while performing these measurements in a
similar way as when they were subjected to imaging.
Subsequently, a venous cannula was inserted into the
centre of the tumor, and the probe was inserted retro-
gradely through the cannula, which was then removed.
The investigator followed continuously the location of
the probe and the body temperature of the mouse
during the whole recording time. The recordings were
continued until the tissue oxygen tension (ptiO2) level
remained stable for at least 20 min.
Statistical methods
Variables are reported as medians and interquartiles, un-
less otherwise stated. Pearson correlation coefficients
were used to correlate PET parameters (the [18F]FDG
scan and the first and second [18F]EF5 scans) with the
percentage of tumor growth rate per day. In addition,
Pearson correlation coefficient was used to correlate the
tumor volume and the uptake of [18F]EF5. P values less
than 0.05 were considered statistically significant (two-




There was a considerable variability in growth rates of
the individual tumors (Table 2). During the exponential
growth phase; the median percentage of tumor growth
rate per day was 8.45 (6.64 to 11.92). The median tumor
volume at the time of the last scan was 321 mm3 (183 to
569 mm3). An example of the tumor growth curve is
presented in Figure 1A.
Uptake of PET tracers in xenografts
The uptake of [18F]EF5 and [18F]FDG in the tumors is
presented in Table 2. Figure 1 shows typical PET/CT im-
ages and time-activity-curves of one tumor. The median
whole tumor uptake for [18F]FDG was higher (1.75% ID/g)
than for [18F]EF5 (first and second scans: 1.40% ID/g
and 1.50% ID/g, respectively). There were considerable
variations between the repeated [18F]EF5 scans. As seen in
Figure 2, the uptake in the tumors could either increase or
decrease during the tumor growth.
The percentage of tumor growth rate per day and
[18F]FDG uptake seemed to point to a relationship (r =
0.348, p = 0.32) as did [18F]EF5 uptake in the first scan
(r = 0.398, p = 0.25), although neither of the relation-
ships was statistically significant. Instead, the uptake of
[18F]EF5 in the latter scan showed a stronger correlation
with the tumor growth rate (r = 0.766) which was statis-
tically significant (p = 0.01) (Figure 3). Tumor growth
rate was also correlated with the HC 10% uptake of the
tumor (Figure 4) for all three scans. The strongest, al-
though not a significant relationship, was seen between
the HC 10% uptake of the second [18F]EF5 scan and
tumor growth rate per day (r = 0.503, p = 0.14).
There was no correlation in the latter scan between
the [18F]EF5 uptake and the tumor volume (r = −0.217,
p = 0.55). However, the tumor volume seemed to be in
relation with the [18F]EF5 uptake in the first scan, when
the tumors were smaller (r = 0.510, p = 0.13), although
this correlation did not reach statistical significance.
Direct oxygen measurements
Two tumors (nr 4 and 5) were measured with Licox
system. Both tumors were clearly hypoxic according to
their ptiO2 values, which were 3.6 and 0.9 mmHg, respect-
ively. An example of direct oxygen measurements is pre-
sented in Figure 1D.
Discussion
A high growth rate and hypoxia are the characteristics
of HNC with poor prognosis. Certainly, there are many
other important features contributing to a low survival





























1 8 1.59 2.15 0.54 0.90 0.99 1.60 26 29 183 8.20
2 8 1.31 2.21 1.41 3.45 0.68 1.03 26 91 685 8.69
3 8 1.51 2.31 1.39 2.86 0.95 1.15 26 45 275 7.38
4 34 1.80 2.99 2.35 3.15 2.42 2.89 5 325 367 14.08
5 34 3.06 4.44 1.96 2.56 2.75 3.64 7 330 408 11.92
6 74A 2.23 3.71 1.30 1.80 1.75 2.56 36 223 660 6.64
7 74A 2.76 3.89 0.88 1.30 2.67 3.34 14 53 105 12.08
8 70 1.06 2.89 1.50 3.18 1.37 2.62 15 340 569 6.11
9 70 1.70 5.13 1.39 2.17 1.03 2.15 35 93 274 5.29
10 70 4.58 10.89 2.16 3.28 1.62 3.39 35 30 168 9.17
Median 1.75 3.35 1.40 2.71 1.50 2.59 26 92 321 8.45



















Figure 2 Whole tumor uptake of [18F]EF5 in the repeated PET/CT scans.
Figure 1 Growth curve, PET data, and partial ptiO2 measurements from tumor nr 5. (A) Growth curve of the tumor with the starting point
and end point of the exponential growth period. (B) Axial PET/CT images of the tumor. (C) Time-activity curves of the tracer uptake into the
tumor in the [18F]FDG scan and in the first and second [18F]EF5 scan. (D) Measurements of the partial pressure of oxygen in the tumor.




Figure 3 Whole tumor uptake values compared to the tumor
growth rate. The black line indicates the linear relationship between
tumor growth rate and the tracer uptake in the [18F]FDG-scans (A) and
in the first (B) and second (C) [18F]EF5 scans. UT-SCC8 (filled triangle),
UT-SCC34 (filled diamond), UT-SCC74A (filled circle), and UT-SCC70
(filled square).
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[17]. Nonetheless, of these features, tumor growth rate is
probably the simplest to measure in experimental stud-
ies. In spite of this, there is only limited data on the as-
sociation between [18F]FDG uptake and tumor growth
rate in HNC in different experimental systems. Hypoxia
has been associated with rapidly growing tumors in gen-
eral [10], although the level of hypoxia does not usually
correlate with tumor volume [13]. As far as we are aware,
none of the currently known hypoxia PET tracers have
been evaluated to determine how well they reflect rela-
tionship with the tumor growth rate.Another novel perspective in this study was the per-
formance of repeated [18F]EF5 imaging with time at differ-
ent stages of the exponential tumor growth. The intention
was to compare the whole tumor uptake of those two
scans in order to evaluate the utility of [18F]EF5 imaging
to detect tumor hypoxia progression in an experimental
setting. For practical reasons, e.g., unpredictable tumor
growth rates, we could not utilize a constant time frame
between the [18F]EF5 scans. Instead, we were able to per-
form the [18F]FDG scans and the latter [18F]EF5 scans on
consecutive days. In addition, we measured the oxygen
level with the Licox system. Both measured tumors were
found to be hypoxic, and the [18F]EF5 uptake values of the
latter scan in these tumors were higher than the corre-
sponding median [18F]EF5 uptake value (Table 2).
There was a considerable variation between the tumor
[18F]EF5 uptakes of the two scans, as shown in Figure 2.
Probably due to the growth of tumors, some variation was
evident between the two scans. It is also well known that
the uptake rate of hypoxia PET tracers in tumors may fluc-
tuate over time, probably due to changes in acute hypoxia.
Nonetheless, the time scale and pattern for these changes
remain poorly understood, and conflicting findings with
different tracers in experimental and human studies have
been reported. Busk et al. performed an experimental re-
producibility study with mice carrying human cervix
tumor xenografts. In that study, a high correlation was
noted between the two PET scans with the hypoxia tracer
18F-labeled fluoroazomycin arabinoside ([18F]FAZA) per-
formed on consecutive days [18]. Nehmeh et al. detected
considerable variation among repeated [18F]FMISO scans
performed three days apart in patients with HNC [19],
whereas Okamoto et al. reported high reproducibility
of [18F]FMISO scans conducted 2 days apart in another
clinical study with HNC patients [20]. Nevertheless, very
little is known about changes in the PET tracer uptake in
a hypoxic malignant tumor over a larger time scale and
even less is known about the potential relationship of
these changes with the behavior of the tumor.
In our study, only a weak positive correlation (r =
0.348) was found between the tumor growth rate and
the [18F]FDG uptake in the late period of exponential
tumor growth. Based on our previous knowledge of tumor
growth rate and metabolic activity in comparable cell lines
[21], the correlation between [18F]FDG uptake and tumor
growth rate would have been expected to be somewhat
stronger. There was only a weak positive correlation (r =
0.398) between the [18F]EF5 uptake of the first scan and
the tumor growth rate, in contrast to the clear correlation
(r = 0.766) noted between the latter [18F]EF5 scan which
was performed during the late phase of exponential
growth. We also determined the tumor uptakes as HC
10%. Only the HC 10% value in the second [18F]EF5 scan









































































r  = 0.022
p = 0.95
r  = 0.053 
p = 0.89 
r  = 0.503
p = 0.14 
Figure 4 Hottest cluster (HC 10%) tumor uptake values compared to the tumor growth rate. The black line indicates the linear relationship
between tumor growth rate and the tracer uptake in the [18F]FDG-scans (A) and in the first (B) and second (C) [18F]EF5 scans. UT-SCC8 (filled triangle),
UT-SCC34 (filled diamond), UT-SCC74A (filled circle), and UT-SCC70 (filled square).
Silvoniemi et al. EJNMMI Research 2014, 4:65 Page 7 of 9
http://www.ejnmmires.com/content/4/1/65tumor growth rate. Accordingly, we conclude that the up-
takes of [18F]FDG and [18F]EF5 in the first scan are inde-
pendent of the tumor growth rate. More rapidly growing
tumors showed a higher [18F]EF5 uptake at the late period
of the exponential growth phase. The biological back-
ground for this relationship is obscure since hypoxia itself
may drive tumor progression, but rapid cell proliferationin the tumor would be expected to contribute to the de-
velopment of hypoxia [10].
One limitation of this study is the small and variable
tumor volume, particularly in the first [18F]EF5 scans.
As known, the partial volume effect may lead to under-
estimation of the detected radioactivity in tumors that
are of a size less than three times the full width at half
Silvoniemi et al. EJNMMI Research 2014, 4:65 Page 8 of 9
http://www.ejnmmires.com/content/4/1/65maximum of the reconstructed image resolution [22].
This is a fact that has to be kept in mind when consider-
ing further conclusions regarding our results from the
first [18F]EF5 scans. Nevertheless, at the latter [18F]EF5
scan, tumors were larger, and hence, the risk of biases
introduced by the partial volume effect is not considered
to affect these findings.
The uptake of [18F]EF5 in the latter scan did not correl-
ate with the tumor size (r = −0.217) in our study popula-
tion. This is in line with many previously reported studies,
which have concluded that there is no connection be-
tween tumor size and hypoxia [13-16]. Clearly, a large
tumor size cannot be used as a surrogate marker of poor
oxygenation, and this underlines the fact that similar-sized
tumors may need different radiation doses to become
eliminated. However, although not statistically signifi-
cant, we observed a trend toward a relation between
the [18F]EF5 uptake in the first scan and the tumor vol-
ume (r = 0.510, p = 0.13). This weak relationship might be
explained by the partial volume effect in smaller tumors.
Recent studies and reviews on PET/CT imaging of tumor
hypoxia have highlighted that there are challenges both
in the detection of tumor hypoxia and in the clarification
of the relevance of these results. Spatial and temporal
variation in tumor hypoxia occurs frequently, but this
phenomenon is still inadequately understood. Therefore
the future studies on hypoxia PET/CT-imaging should be
designed in such a way that the utility of a new tracer or a
new method can be evaluated by comparing the imaging
data not only to hypoxia-related markers or to direct oxy-
gen measurements of the tumor but also to the behavior
of the tumor and treatment outcome [5]. This study dem-
onstrated the initial relationship between [18F]EF5 uptake
of the tumor and tumor growth rate, but a larger study
population would be needed to confirm this observation.
It is interesting that this relationship was stronger for a
hypoxic than for a metabolic tracer; this may be due to
timing of the second measurement when the hypoxic frac-
tion is large.
Conclusions
We found that the uptake of the hypoxia tracer [18F]EF5
in the late phase of exponential tumor growth is associ-
ated with the tumor growth rate in mice carrying HNC
xenografts. A considerable variation in the uptake of
[18F]EF5 was also detected between the two scans. The
temporal variation of tumor hypoxia remains a poorly
understood phenomenon.
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